Ever heard someone say you only need glucagon when you’re passed out? In my sit down with Xeris CEO Paul Edick, we discussed the misperceptions and myths surrounding glucagon as a rescue prescription. From the lack of education within the healthcare community to the patients’ misinformation themselves, this is a call to action for patient advocacy and advocates to get everyone with diabetes on a rescue glucagon like Gvoke. That starts with learning proper usage and correct knowledge. This episode could save lives, and I am fully on board with sharing the Gvoke mission!
Time Stamps:
- (03:20) Paul’s journey to becoming CEO of Xeris and the “elegance” of Xeris technology
- (04:48) The growth of Xeris
- (06:41) What is glucagon?
- (07:56) The fallacy and myths around glucagon and its proper use.
- (09:32) Why did it take so long to innovate glucagon?
- (10:50) The statistics of hypoglycemia
- (12:33) What is considered a severe low and clinical trials
- (15:37) Using education to combat fears of glucagon and going low
- (18:15) The number one battle Xeris faces in getting Gvoke into more hands
- (20:16) Xeris’ role in educating the healthcare community on proper usage and knowledge
- (22:43) A Call to Action for patient advocacy and advocates
- (23:33) Standardized procedures for discussing rescue glucagon
- (26:00) What Xeris learned from bringing in social influencers to ask questions
- (29:08) The future of Xeris, their mission, and the startling statistical comparison to EpiPen for allergies
What to do now:
- Follow me @lauren_bongiorno and @riselyhealth on Instagram to stay in the loop for when new episodes drop.
- Learn more and apply for the January 2024 Decide and Conquer Bootcamp HERE.
Disclaimer: Nothing you hear on the Reclaim your Rise podcast should be a substitute for personalized professional medical advice. Please always consult your physician or other medical professional before making any changes to your diet, insulin dosages, or healthcare plan.
